ArticleJournal of nanobiotechnology2024

A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.

Zhenzhen Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.